Welcome to our dedicated page for Azenta news (Ticker: AZTA), a resource for investors and traders seeking the latest updates and insights on Azenta stock.
Azenta, Inc. (Nasdaq: AZTA) is a life sciences company focused on cold-chain sample management and multiomics services. News about AZTA often centers on how its sample management solutions, biorepository network and genomic services support drug development, clinical research and advanced cell therapies for pharmaceutical, biotech, academic and healthcare institutions.
On this page, readers can follow company announcements related to financial results, segment performance in Sample Management Solutions and Multiomics, and updates on margin trends and cost structure. Earnings releases and accompanying commentary provide insight into revenue contributions from products and services, as well as the company’s efforts to streamline operations and refine its portfolio.
Azenta’s news flow also includes strategic transactions and capital allocation decisions, such as the definitive agreement to sell its B Medical Systems business and the authorization of a share repurchase program. These items illustrate how the company prioritizes core capabilities and balances investment in growth with returning capital to shareholders.
Another key theme in AZTA news is partnerships and collaborations. Recent releases describe Azenta’s role in supporting the PRECEDE Foundation’s pancreatic cancer early detection efforts through secure sample storage, and its collaboration with Frenova and Nephronomics, where GENEWIZ by Azenta provides genomic sequencing and Azenta manages long-term sample storage for a large kidney disease research program.
Investors and researchers can use this news feed to monitor developments in Azenta’s sample management and multiomics businesses, track major collaborations and stay aware of governance and shareholder-related events such as investor days, conference participation and annual meeting information.
Azenta (Nasdaq: AZTA) will participate in the Raymond James 47th Annual Institutional Investor Conference on March 3, 2026. Management will present beginning at 4:00 PM ET. A live webcast is available via the Azenta investor relations site and a replay will be posted after the event.
Azenta (Nasdaq: AZTA) announced a strategic partnership with Frontier Space to test sample management technologies in space as part of the EGGS-2 mission launched in January 2026.
The collaboration used 42 FluidX 0.26mL tubes in a custom container aboard Frontier's SpaceLab Mk 2 to evaluate thermal management, temperature monitoring, and tube durability under launch and spaceflight conditions.
Azenta (Nasdaq: AZTA) reported Q1 fiscal 2026 continuing operations revenue of $149 million, up 1% year-over-year, adjusted EBITDA of $13 million and non-GAAP diluted EPS of $0.09. Gross margin declined to 42.9%, down 380 basis points, while cash and marketable securities totaled $571 million.
The company entered a definitive agreement to sell B Medical Systems for $63 million and authorized a $250 million share repurchase program through 2028. Fiscal 2026 guidance: organic revenue growth of 3–5% and ~300 bps adjusted EBITDA margin expansion.
Azenta (Nasdaq: AZTA) will announce fiscal first quarter 2026 earnings for the period ended Dec. 31, 2025 on Wednesday, Feb. 4, 2026 before the market opens. The company will host a conference call and live webcast to discuss results on Feb. 4, 2026 at 8:30 a.m. Eastern Time. Analysts, investors and media can access the live webcast at https://investors.azenta.com/events. A replay will be available beginning Feb. 5, 2026 at 8:30 a.m. ET.
Azenta (NASDAQ: AZTA) signed a binding agreement to sell its B Medical Systems business to THELEMA S.À R.L. for a purchase price of US$63 million. The sale is expected to close on or before March 31, 2026. Azenta described the divestiture as a step to simplify its portfolio and prioritize core capabilities, and said proceeds will be deployed to strengthen the company and support long-term value creation for shareholders. William Blair served as exclusive financial advisor and Taylor Wessing served as legal counsel.
Azenta (Nasdaq: AZTA) announced a Board-approved $250 million share repurchase program.
The program began on Dec 9, 2025 and runs through Dec 31, 2028 unless earlier extended or terminated. Repurchases may be executed via open-market purchases, privately negotiated transactions, or other methods compliant with Rules 10b-18 and 10b5-1. The authorization is discretionary and does not obligate Azenta to buy any specific dollar amount or number of shares; repurchases can be commenced, suspended, modified, or discontinued at any time.
Management said the buyback is part of a capital allocation strategy alongside productivity, organic growth, and disciplined M&A to enhance long-term shareholder value.
Azenta (Nasdaq: AZTA) reported Q4 FY2025 revenue of $159M (+6% YoY; organic +4%) and full‑year revenue of $594M (+4% YoY; organic +3%).
Fiscal 2025 Adjusted EBITDA was $66M with an Adjusted EBITDA margin of 11.2% (up 310 bps YoY). GAAP operating loss was $27M; GAAP diluted EPS from continuing operations was $0.52 and total diluted EPS was ($1.30). Cash and equivalents plus marketable securities totaled $546M.
Guidance for FY2026 calls for organic revenue growth 3–5% and ~300 bps of adjusted EBITDA margin expansion.
Azenta (Nasdaq: AZTA) will release fiscal fourth quarter and full year 2025 results for the period ended September 30, 2025 on Friday, November 21, 2025 before the market opens.
The company will host a live conference call and webcast to discuss results on November 21, 2025 at 8:30 a.m. Eastern Time. Analysts, investors and media can access the live webcast at https://investors.azenta.com/events. A replay will be available beginning 8:30 a.m. ET on November 22, 2025.
Azenta (Nasdaq: AZTA) announced a strategic partnership with the PRECEDE Foundation on Nov 4, 2025 to support early detection of pancreatic cancer by providing secure biorepository storage and streamlined logistics for PRECEDE study samples.
PRECEDE unites more than 60 academic medical centers and maintains the world's largest high-risk patient cohort combining longitudinal clinical data with biospecimen tracking. Pancreatic cancer currently has a five-year survival rate of 13%, and PRECEDE's stated goal is to raise that to 50% within the next decade. Azenta frames the agreement as reinforcing its position in sample management for clinical and diagnostic research and will support PRECEDE ahead of its Annual Meeting in November.
Azenta (Nasdaq: AZTA) will host an Investor Day on Wednesday, December 10, 2025 at its biorepository facility in Indianapolis, Indiana. The event runs 8:30 AM–3:30 PM ET and includes an invite-only morning facility tour plus afternoon executive presentations and Q&A led by John Marotta (CEO) and Lawrence Lin (EVP & CFO).
The afternoon presentations will be webcast beginning at 1:00 PM ET, with a replay available the following day on Azenta's Investor Relations website. In-person attendance is by invitation and requires advanced registration.